Syner-G

SEPTEMBER 20, 2023

pharmaceutical company to oversee a 6 month, DS manufacturing as Person-In- Plant (PIP) and assist with preparation of associated submission documents related to Phase III clinical trial batches. Download The Case Study The post Process improvements and in-person monitoring help U.S.

Process Improvement 40

Process Improvement Pharmaceutical Companies Pharmaceutical Companies Documentation 40

GMPSOP

NOVEMBER 19, 2023

Additional documents included each month. Trending will help identify product and process improvements. If significant trends are identified, they should be documented, and changes should be made to avoid out-of-specification results. The number of batches manufactured, released and rejected should be documented.

Documentation 52

Documentation Packaging Method Validation Process Improvement 52

European Pharmaceutical Review

JANUARY 27, 2025

The emergence of huge pharmaceutical companies with discrete centres of excellence in geographically dispersed locations has upended the classic model of one-stop shopping for all development functions. An example of the structured and modular tech transfer approach is shown in Figure 2.

Communication 52

Communication Documentation Pharmaceutical Companies Pharmaceutical Companies 52